Epizyme, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
In the following press release, the company presented a preclinical characterization of EPZ-5676, which Epizyme is developing for the treatment of MLL-r leukemia.
“EPZ-5676, a potent and selective small-molecule inhibitor of DOT1L, sustained tumor growth inhibition in animal models of MLL-r leukemia, including durable effects after drug dosing is discontinued.” Read the full article.
Epizyme, Inc. operates as a clinical stage biopharmaceutical company. The company discovers, develops and plans to commercialize therapeutics for patients with genetically defined cancers. It engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. The company products include Tazemetostat, which is used for the treatment of multiple types of hematological malignancies and genetically defined solid tumors; and Pinometostat, which is used for treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA. [Source: MarketWatch]
Company Website: http://www.epizyme.com